The abstract is read at the publisher; the summary is JClub's.
Antibody-drug conjugates show transformative clinical successes, but benefits remain limited to a small set of tumor types, with frequent setbacks highlighting unresolved precision oncology challenges.
- Why it matters: ADC development struggles with patient selection, biomarker assay standardization, chemical design, and weak predictive power of existing preclinical models, leaving no validated biomarkers to guide use.
- What they did: This review synthesizes evidence that ADC activity depends on more than target antigen expression, including tumor-intrinsic traits and tumor microenvironment processes, and links efficacy, resistance, and toxicity mechanisms to development failures.
- The result: The findings support viewing ADCs as tumor-ecosystem-targeting therapies with multidimensional determinants, informing biomarker strategies, combination approaches, next-generation platforms, and curative-intent frameworks.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.